IMMUNIC CEO granted 1M stock options at $13.05

IMMUNIC, INC. granted its Chief Executive Officer, Erik Lundgren, stock options covering 1,000,000 shares of common stock.

Rhea-AI Filing Summary

IMMUNIC, INC. granted its Chief Executive Officer, Erik Lundgren, stock options covering 1,000,000 shares of common stock. The options have an exercise price of $13.05 per share and expire on May 22, 2036. They are time-vested: 25% vest on May 22, 2027, with the remaining 75% vesting in 36 equal monthly installments, contingent on his continued employment.

Insider Trade Summary

Grant/Award: 1,000,000 shares

Grant/Award 1 txn

Insider Lundgren Erik

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	1,000,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 1,000,000 contracts (Direct)

Footnotes (1)

1. F1. The options disclosed on this Form 4 are time vested; twenty-five percent (25%) of the shares underlying the options awarded to the Reporting Person will vest on May 22, 2027, and the remaining seventy-five percent (75%) vesting on a monthly basis in thirty-six (36) equal installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date. The Reporting Person became a director and a Section 16 insider on June 1, 2026.

Key Figures

Options granted: 1,000,000 stock options Exercise price: $13.05 per share Expiration date: May 22, 2036 +3 more

6 metrics

Options granted 1,000,000 stock options Grant to CEO Erik Lundgren on May 22, 2026

Exercise price $13.05 per share Exercise price of granted stock options

Expiration date May 22, 2036 Option term end date

Initial vesting tranche 25% on May 22, 2027 First vesting date for granted options

Remaining vesting schedule 75% over 36 monthly installments Ongoing vesting after May 22, 2027

Post-transaction options held 1,000,000 options Direct holdings following reported grant

Key Terms

time vested, Section 16 insider, stock option, vesting

4 terms

time vested financial

"The options disclosed on this Form 4 are time vested; twenty-five percent (25%) of the shares..."

Section 16 insider regulatory

"The Reporting Person became a director and a Section 16 insider on June 1, 2026."

stock option financial

"The options disclosed on this Form 4 are time vested; twenty-five percent (25%) of the shares..."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vesting financial

"the remaining seventy-five percent (75%) vesting on a monthly basis in thirty-six (36) equal installments..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IMMUNIC, INC. (IMUX) CEO Erik Lundgren report in this Form 4?

Erik Lundgren reported a grant of stock options for 1,000,000 shares of Immunic common stock. The options were awarded as compensation and are not an open-market purchase, reflecting a time-vested equity incentive tied to his ongoing service as Chief Executive Officer.

What is the exercise price and term of the new IMUX CEO stock options?

The CEO’s new stock options have an exercise price of $13.05 per share and expire on May 22, 2036. This gives him the right, but not the obligation, to buy up to 1,000,000 shares at that price before expiration.

How do the IMMUNIC, INC. CEO options granted on May 22, 2026 vest?

The options are time vested: 25% of the underlying shares vest on May 22, 2027. The remaining 75% vest in 36 equal monthly installments afterward, conditioned on Erik Lundgren remaining an employee of Immunic, Inc. in good standing through each vesting date.

Is the IMUX CEO Form 4 transaction a stock purchase or a compensation grant?

The Form 4 reports a compensation grant, not an open-market stock purchase. Erik Lundgren received 1,000,000 stock options at a $13.05 exercise price as a grant or award, classified as a derivative acquisition rather than a cash share purchase in the market.

How many stock options does the IMMUNIC, INC. CEO hold after this transaction?

Following the reported transaction, Erik Lundgren holds 1,000,000 stock options directly. These options are tied to Immunic common stock, exercisable at $13.05 per share, and subject to the specified vesting schedule and the overall expiration date of May 22, 2036.

When did Erik Lundgren become a Section 16 insider at IMMUNIC, INC.?

Erik Lundgren became a director and Section 16 insider on June 1, 2026, according to the footnote. Section 16 status subjects insiders to specific SEC reporting requirements, including timely disclosure of equity grants and other transactions in company securities on Forms 3, 4, and 5.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 05:57 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lundgren Erik

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$13.05	05/22/2026		A		1,000,000		(1)	05/22/2036	Common Stock	1,000,000	$0.00	1,000,000	D

Explanation of Responses:

1. The options disclosed on this Form 4 are time vested; twenty-five percent (25%) of the shares underlying the options awarded to the Reporting Person will vest on May 22, 2027, and the remaining seventy-five percent (75%) vesting on a monthly basis in thirty-six (36) equal installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date. The Reporting Person became a director and a Section 16 insider on June 1, 2026.

	/s/ Grant Levine, attorney-in-fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)